Previous studies in the mouse models showed that many phenotypic manifestations could be attributed to an increase in the activity of TGF-β45–47, and that treatments with antibodies against TGF-β reportedly prevented the development of myxomatous mitral valve disease and emphysematous abnormalities in mouse models of MFS46,47. The gene discussed is TGFB1; the disease is mitral valve disorder.